P. McLaughlin, L. Odom, P. Arnett, G. Thomas, Shannon Orehek, I. Zagon
{"title":"Length of Disease More than Therapy Impacts Anxiety and Depression in Multiple Sclerosis","authors":"P. McLaughlin, L. Odom, P. Arnett, G. Thomas, Shannon Orehek, I. Zagon","doi":"10.33425/2692-7918.1043","DOIUrl":null,"url":null,"abstract":"Persons with multiple sclerosis (PwMS) often report a reduced quality of life related to their anxiety and depression associated with the biological unknowns of MS. The COVID-19 pandemic increased the risk of anxiety due to the uncertainties related to vaccine efficacy and immune-suppressing disease-modifying therapies. PwMS were recruited from the Neurology Clinic of the Penn State Hershey Medical Center and asked to complete a demographic questionnaire and surveys on depression (MS-Beck Depression Inventory, MS-BDI) and the Hospital Anxiety and Depression Scale (HADS). The rationale for the study is to determine whether treatment modalities, age, and length of disease impacted anxiety and/or depression in PwMS. Data from 150 participants were included in the analyses. The overall mean age was 54.6 years with a 3.7:1 female:male ratio and mean length of disease of approximately 17 years. Mean scores of the HADS-D, and high scores (> 8) were 4.68 ± 0.3 and 10.0 ± 0.32, respectively, with no differences between males and females. The mean HADS-A score was 6.15 ± 0.36 with significant differences recorded between male and females. The mean high HADS-A score was 10.77 ± 0.40, with no differences between sexes. The mean MS-BDI score was 4.15 ± 0.7 with no differences between males and females. Analyses of anxiety scores in relationship to length of disease revealed no differences between males and females. Anxiety scores did not differ for PwMS on different disease-modifying therapies. In conclusion, the number of years that PwMS had the disease impacted anxiety levels more than the age or treatment regimen..","PeriodicalId":21130,"journal":{"name":"Restorative neurology and neuroscience","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Restorative neurology and neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33425/2692-7918.1043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Persons with multiple sclerosis (PwMS) often report a reduced quality of life related to their anxiety and depression associated with the biological unknowns of MS. The COVID-19 pandemic increased the risk of anxiety due to the uncertainties related to vaccine efficacy and immune-suppressing disease-modifying therapies. PwMS were recruited from the Neurology Clinic of the Penn State Hershey Medical Center and asked to complete a demographic questionnaire and surveys on depression (MS-Beck Depression Inventory, MS-BDI) and the Hospital Anxiety and Depression Scale (HADS). The rationale for the study is to determine whether treatment modalities, age, and length of disease impacted anxiety and/or depression in PwMS. Data from 150 participants were included in the analyses. The overall mean age was 54.6 years with a 3.7:1 female:male ratio and mean length of disease of approximately 17 years. Mean scores of the HADS-D, and high scores (> 8) were 4.68 ± 0.3 and 10.0 ± 0.32, respectively, with no differences between males and females. The mean HADS-A score was 6.15 ± 0.36 with significant differences recorded between male and females. The mean high HADS-A score was 10.77 ± 0.40, with no differences between sexes. The mean MS-BDI score was 4.15 ± 0.7 with no differences between males and females. Analyses of anxiety scores in relationship to length of disease revealed no differences between males and females. Anxiety scores did not differ for PwMS on different disease-modifying therapies. In conclusion, the number of years that PwMS had the disease impacted anxiety levels more than the age or treatment regimen..
期刊介绍:
This interdisciplinary journal publishes papers relating to the plasticity and response of the nervous system to accidental or experimental injuries and their interventions, transplantation, neurodegenerative disorders and experimental strategies to improve regeneration or functional recovery and rehabilitation. Experimental and clinical research papers adopting fresh conceptual approaches are encouraged. The overriding criteria for publication are novelty, significant experimental or clinical relevance and interest to a multidisciplinary audience. Experiments on un-anesthetized animals should conform with the standards for the use of laboratory animals as established by the Institute of Laboratory Animal Resources, US National Academy of Sciences. Experiments in which paralytic agents are used must be justified. Patient identity should be concealed. All manuscripts are sent out for blind peer review to editorial board members or outside reviewers. Restorative Neurology and Neuroscience is a member of Neuroscience Peer Review Consortium.